Alzamend Neuro, a clinical-stage biopharmaceutical company advancing a novel lithium delivery candidate AL001 for bipolar and major depressive disorders, remains pre-revenue with ongoing R&D expenses driving deep operating losses. Over the past four years, net losses have trended downward but remain substantial reflecting investment in Phase II trials. Recent issuance of equity through at-the-market (ATM) offerings signals continuing financing needs to fund clinical development. Key growth drivers hinge on successful trial outcomes and regulatory approval, but capital constraints and execution risks weigh heavily on near-term prospects.